agilon health (AGL) Stock Trades Up, Here Is Why

Agilon Health (AGL) reported Q2 2026 revenue of $1.49B, up 7% y/y, and adjusted EBITDA of $70M, above guidance, citing favorable medical cost development and higher risk adjustment revenue. FY2026 guidance was raised to $5.78B-$5.86B revenue and $75M-$95M adjusted EBITDA. Medicare Advantage membership fell to 437k. Cash and marketable securities were $257M at June 30, 2026.

AGL Energy shares rose 5.4% to A$8.6 after the company reported FY26 results. Underlying EBITDA increased 2% to A$2.10 billion, operating free cash flow rose 60% to A$850 million, and profit after tax was A$756 million. It declared a fully franked final dividend of 26 cents, taking FY26 total to 50 cents, and guided FY27 payout ratio of 55–60%.

Agilon Health (AGL) reported Q2 margin and adjusted EBITDA above guidance midpoints, citing favorable prior-year development, higher risk-adjustment revenue estimates, and medical-cost trend developments. The company ended Q2 with $257M cash and marketable securities and raised 2026 guidance to about $5.8B revenue, $485M medical margin, and $85M adjusted EBITDA. It also cut 2025 medical-cost trend to 5.8% and expects Q3 break-even adjusted EBITDA.

Agilon Health (NYSE:AGL) reported Q2 CY2026 revenue of $1.49 billion, up 7.2% year over year, exceeding Wall Street estimates by 2.8%. Next-quarter revenue guidance was $1.46 billion at the midpoint, about 3.7% above expectations. GAAP EPS was $1.04, well above consensus, and the stock rose 2.6% to $110.51.

agilon health, inc. (AGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 agilon health Reports Second Quarter 2026 Results Revenue increase 7% to $1.49 billion Raises Full-Year 2026 Total Revenues, Medical Margin, and Adjusted EBITDA Guidance Westerville, O.H., August 5, 2026 – agilon health, inc. (NYSE: AGL), the trusted partner empoweri

AGL Energy (ASX:AGL) shares fell 3.67% to close at A$8.13, hitting a new 52-week low after briefly breaking A$8.00. The drop follows FY26 underlying NPAT guidance of A$610m to A$680m and regulatory pressure, including AER-mandated price cuts of up to 10% for 2026-27 default offers.